cardiometabol
disord
includ
obes
diabet
cardiovascular
diseas
among
sever
health
problem
worldwid
enzymat
inhibitor
first
develop
antidiabet
reagent
preserv
incretin
hormon
promot
postprandi
insulin
secret
shown
anim
studi
incretinbas
therapi
benefici
effect
cardiovascular
diseas
recent
studi
demonstr
novel
noncatalyt
function
may
play
role
cardiometabol
diseas
although
role
inhibitionmedi
incretin
effect
wellreview
littl
inform
incretinindepend
action
introduc
cardiometabol
diseas
current
review
summar
catalyt
depend
independ
effect
inhibit
cardiometabol
diseas
dipeptidyl
also
known
adenosin
deaminas
bind
protein
adbp
typeii
integr
membran
glycoprotein
recent
gain
attent
owe
role
catalyt
degrad
incretin
develop
inhibitor
class
antidiabet
medic
wide
accept
due
eas
administr
lack
seriou
sideeffect
wide
believ
inhibit
benefici
effect
cardiovascular
diseas
howev
recent
complet
largescal
phase
phase
clinic
trial
examin
savortimi
show
signific
improv
primari
cardiovascular
endpoint
patient
treat
enzymat
inhibitor
compar
placebo
call
question
cardiovascular
efficaci
agent
howev
must
note
trial
test
whether
enzymat
inhibit
benefici
short
term
import
nonenzymat
effect
test
addit
catalyt
action
also
exert
catalyt
independ
function
interact
number
ligand
adenosin
deaminas
ada
fibronectin
middl
eastern
respiratori
syndromecorona
viru
spike
protein
cardiovascular
effect
believ
majorli
mediat
incretindepend
mechan
recent
advanc
noncatalyt
activ
suggest
incretinindepend
action
may
also
play
essenti
role
cardiometabol
diseas
howev
littl
inform
incretinindepend
action
cardiometabol
diseas
introduc
previou
review
review
review
import
catalyticdepend
versu
independ
activ
pathophysiolog
cardiometabol
disord
also
provid
recent
clinic
trial
evid
test
effect
cardiovascular
diseas
belong
famili
consist
sever
structur
homolog
serin
peptidas
quiescent
cell
prolin
dipeptidas
qpp
also
call
fibroblast
activ
protein
fap
protein
famili
abl
cleav
ntermin
dipeptid
protein
contain
prolin
alanin
penultim
posit
first
identifi
glycylprolin
naphthylamidas
subsequ
purifi
rat
liver
pig
kidney
cytoplasm
aa
transmembran
domain
extracellular
domain
contain
domain
eightblad
domain
fig
c
termin
extracellular
domain
respons
catalyt
activ
catalyt
triad
bind
number
protein
includ
ada
matrix
protein
function
homodim
reli
broad
intermolecul
contact
contribut
hydrolas
domain
extend
strand
blade
iv
catalyt
activ
depend
upon
dimer
state
residu
residu
play
critic
role
substrat
cleavag
glycosyl
also
appear
import
determin
catalyt
activ
glycosyl
human
propos
control
assembl
assembl
tetram
cell
surfac
circul
linkag
two
homodim
wide
distribut
throughout
bodi
particularli
high
express
exocrin
gland
absorpt
epithelia
human
found
high
level
brush
border
small
intestin
kidney
proxim
tubular
cell
glomerular
cell
hepatocyt
activ
leukocyt
signific
amount
also
present
blood
vessel
particularli
endotheli
cell
among
hematopoiet
cell
express
highest
level
cell
especi
cell
lower
level
monocyt
dendrit
cell
express
increas
monocyt
differenti
macrophag
well
cell
activ
inde
describ
cell
activ
marker
number
year
organ
level
highli
express
solid
organ
includ
kidney
spleen
lung
pancrea
prostat
solubl
homodim
molecular
weight
rang
kda
form
higher
molecular
weight
assembl
migrat
complex
solubl
lack
cytoplasm
transmembran
domain
preserv
catalyt
activ
major
cellular
sourc
circul
appear
bone
marrow
cell
adipocyt
howev
whether
cleav
membran
secret
unclear
studi
investig
viral
liver
infect
suggest
shed
membran
bound
studi
suggest
secretori
mechan
evidenc
fact
detect
lumen
secretori
granul
pancreat
cell
exocyt
secretori
lysosom
natur
killer
cell
member
famili
includ
fap
fap
also
known
sepras
kda
membran
glycoprotein
dipeptidylpeptidas
type
collagenas
activ
share
sequenc
ident
fap
absent
produc
low
level
normal
adult
tissu
baselin
condit
induc
respons
inflammatori
condit
tumor
fap
express
level
correl
prognosi
number
malign
target
fap
epithelialderiv
solid
tumor
shown
inhibit
tumor
growth
fap
associ
thincap
human
coronari
fibroatheromata
contribut
type
collagen
breakdown
fibrou
cap
origin
fap
plaqu
interestingli
shown
deriv
smooth
muscl
cell
rather
macrophag
express
correl
degre
inflamm
plasma
level
fap
shown
invers
correl
mortal
patient
ac
point
diverg
regul
plasma
vs
tissu
level
fap
wide
distribut
across
rang
mammalian
tissu
locat
intracellular
vesicl
secret
upon
activ
interestingli
bear
signific
nucleotid
amino
acid
homolog
wherea
order
catalyt
amino
acid
serasphi
ident
space
catalyt
triad
dissimilar
suggest
differ
substrat
specif
knockout
mice
embryon
lethal
condit
knockdown
specif
cell
type
neuroendocrin
cell
express
neurogenin
pancrea
well
region
hypothalamu
brain
stem
display
phenotyp
stark
contrast
knockout
mice
knockdown
mice
unalt
level
activ
present
hyperinsulinemia
accompani
mark
impair
glucos
toler
insulin
resist
enhanc
liver
steatosi
viscer
obes
wherea
knockout
mice
resist
dietinduc
obes
insulin
resist
find
suggest
dipeptidas
may
distinct
substrat
specif
oppos
function
role
human
share
signific
homolog
ident
amino
acid
wherea
less
homolog
eg
ident
amino
acid
span
amino
acid
contrast
express
cytoplasma
share
substrat
specif
base
vitro
assay
util
nativ
peptid
peptid
pseudosubstr
howev
physiolog
relev
natur
substrat
function
vivo
known
recent
util
cytosolwid
analysi
proteom
human
ovarian
cancer
line
stabli
transfect
use
termin
amin
isotop
label
substrat
approach
recent
studi
identifi
candid
natur
substrat
pathway
affect
overexpress
cleavag
substrat
investig
vitro
substrat
confirm
malditof
mass
spectrometri
includ
two
high
confid
calreticulin
adenyl
kinas
uniqu
cleavag
identifi
demonstr
similar
enzym
specif
larg
substrat
overlap
enzym
adenyl
kinas
play
key
role
cellular
energi
nucleotid
homeostasi
vitro
studi
demonstr
nonenzymat
role
cell
migrat
prolifer
apoptosi
exact
physiolog
role
dipeptidas
invivo
substrat
remain
poorli
defin
alter
express
studi
varieti
diseas
condit
includ
cardiometabol
diseas
shown
express
catalyt
activ
enhanc
diabet
vitro
expos
high
glucos
human
glomerular
endotheli
cell
display
enhanc
express
activ
line
find
circul
activ
report
increas
patient
type
diabet
posit
correl
level
diabet
patient
increas
circul
activ
result
reduct
plasma
fast
respons
meal
addit
circul
activ
express
cell
report
increas
patient
howev
also
report
suggest
decreas
circul
activ
patient
probabl
patient
includ
studi
antidiabet
agent
medic
report
reduc
circul
sever
widelyus
antidiabet
agent
metformin
thiazolidinedion
pioglitazon
report
reduc
circul
cell
enhanc
express
hepat
also
report
nonalcohol
fatti
liver
diseas
express
may
advers
affect
glucos
metabol
liver
diseas
vitro
stimul
cell
high
glucos
increas
express
wherea
insulin
fatti
acid
cholesterol
addit
cardiometabol
diseas
alter
express
also
report
mani
diseas
rheumatoid
arthriti
system
lupu
erythematosu
major
depress
allograft
reject
signal
pathway
mediat
complet
understood
known
may
vari
depend
cell
type
context
microenviron
hepatocyt
nuclear
factor
hnf
signal
transduc
activ
identifi
transcript
factor
express
express
reduc
mutat
promot
contain
consensu
ga
interferon
gammaactiv
sequenc
motif
bp
shown
bind
motif
administr
interferon
retino
acid
result
tyrosin
phosphoryl
subsequ
nuclear
transloc
bind
ga
motif
result
transcript
regul
express
highli
depend
cell
type
express
cell
increas
activ
independ
phenotyp
enhanc
translat
transcript
activ
lymphocyt
decreas
cell
surfac
express
suggest
regulatori
role
translat
probabl
transloc
toward
cell
surfac
stimul
cell
express
higher
level
compar
neg
cell
retino
acid
could
increas
transcript
malign
b
lymphocyt
pathway
also
induc
express
renal
epitheli
cell
contrast
express
natur
killer
cell
induc
express
gingiv
fibroblast
shown
regul
recent
studi
demonstr
also
contribut
upregul
express
epitheli
cell
stromal
cell
wound
dermi
member
dipeptidyl
peptidas
famili
protein
function
ntermin
dipeptidas
prefer
prolin
alanin
residu
penultim
posit
ie
xpropeptid
x
mean
amino
acid
thu
cleav
xpro
xala
dipeptid
ntermin
end
divers
rang
protein
includ
glucagonlik
peptid
glp
glucosedepend
insulinotrop
peptid
gip
neuropeptid
npi
cleav
current
avail
inhibitor
clinic
suppress
dipeptidas
function
preserv
function
substrat
substrat
categor
group
regulatori
peptid
chomokin
cytokin
neuropeptid
regulatori
peptid
substrat
includ
gip
gastrinreleas
peptid
grp
growthhormonereleas
factor
ghrf
activ
form
could
rapidli
convert
inact
form
similarli
gip
ghrf
inactiv
convert
gip
ghrf
respect
chemokin
degrad
includ
regul
activ
normal
tcell
express
presum
secret
rant
also
known
macrophag
deriv
chemokin
mdc
also
known
eotaxin
also
known
monokin
induc
mig
also
known
also
known
interferoninduc
tcell
chemoattract
itac
also
known
stromalcellderiv
also
known
alter
specif
mdc
recruit
cell
type
cleavag
ntermin
dipeptid
inactiv
chemotact
activ
chemokin
recent
studi
suggest
also
truncat
number
cytokin
includ
gmcsf
gcsf
epo
genet
ablat
enzymat
inhibit
activ
inhibitor
enhanc
hematopoiesi
bone
marrow
engraft
mice
irradi
chemotherapi
importantli
truncat
gmcsf
could
serv
antagonist
fulllength
gmcsf
truncat
gmcsf
higher
affin
receptor
devoid
bioactiv
neuropeptid
substrat
includ
npi
btype
natriuret
peptid
bnp
peptid
yy
pyy
substanc
p
remov
ntermin
dipeptid
alter
receptor
subtyp
specif
npi
pyy
reduc
activ
substanc
p
bnp
addit
wellknown
peptidas
activ
also
possess
noncatalyt
function
via
interact
rang
ligand
includ
adenosin
deaminas
ada
fibronectin
interact
ligand
play
role
varieti
process
immun
regulatori
function
enhanc
tcell
activ
function
modul
antigenpres
cell
apc
express
cell
repres
marker
cell
activ
upon
activ
percentag
cell
number
molecul
per
cell
elev
cell
surfac
cell
demonstr
abl
directli
provid
costimulatori
signal
bind
ada
engag
ada
enhanc
tcell
activ
activ
activ
antibodi
prolong
enhanc
tyrosin
phosphoryl
varieti
protein
activ
respons
engag
addit
adaindepend
noncatalyt
activ
also
play
role
cell
activ
yu
et
al
report
phytohaemagglutinin
pha
herp
simplex
viru
antigen
hsv
ag
induc
tcell
prolifer
enhanc
solubl
although
show
effect
cell
prolifer
moreov
enzym
inact
mutant
ada
nonbind
mutant
promot
hsv
aginduc
cell
prolifer
indic
effect
solubl
mechanist
independ
enzymat
activ
adabind
capabl
recent
find
show
number
speci
includ
human
bat
macaqu
hors
rabbit
camel
abl
bind
spike
protein
middl
eastern
respiratori
syndromecorona
viru
merscov
mediat
entranc
host
cell
interestingli
overlap
bind
interfac
indic
possibl
manipul
host
immun
respons
merscov
competit
adarecognit
site
oral
introduc
glucos
induc
greater
insulin
respons
intraven
administ
glucos
concept
known
incretin
effect
incretin
hormon
includ
glucagonslik
glucosedepend
insulinotrop
polypeptid
gip
gip
produc
enteroendocrin
l
cell
k
cell
respect
major
type
incretin
peptid
one
primari
function
gip
promot
postprandi
insulin
secret
fig
gip
increas
transcript
biosynthesi
insulin
promot
prolifer
suppress
death
also
shown
abl
enhanc
glucos
sensit
induc
glucos
compet
previous
unrespons
clinic
studi
confirm
blood
glucos
lower
effect
exogen
administr
addit
pancrea
also
reduc
blood
sugar
act
mani
organ
includ
liver
brain
adipos
tissu
intestin
decreas
glycemia
subject
pancreat
clamp
condit
fix
insulin
glucagon
level
suggest
suppress
glucos
product
independ
islet
hormon
diminish
hepat
glucos
product
also
contribut
antihyperglyciemia
effect
also
act
neuropeptid
reduc
food
intak
inhibit
appetit
regul
muscl
glucos
util
insulin
secret
act
brain
receptor
furthermor
also
suppress
gastric
empti
inhibit
adipos
inflamm
promot
adipocyt
format
act
digest
duct
adipos
tissu
despit
plenti
benefit
treatment
limit
short
halflif
halflif
less
min
halflif
gip
less
min
rodent
min
human
gip
activ
form
gip
convert
inact
form
gip
wide
express
enzym
degrad
gip
first
report
earli
enzymat
remov
ntermin
dipeptid
gip
plasma
observ
vitro
experi
use
purifi
human
placenta
subsequ
studi
confirm
metabol
gip
mediat
inde
occur
vivo
accordingli
inhibitor
emerg
novel
therapeut
approach
type
diabet
clinic
incretin
respons
found
impair
patient
type
diabet
enzymat
activ
correl
degre
glucos
homeostasi
suggest
mediat
incretin
degrad
involv
pathogenesi
type
diabet
signific
correl
observ
type
diabet
subject
also
demonstr
higher
activ
control
impair
glucos
toler
inhibitor
class
newli
avail
oral
agent
type
diabet
either
monotherapi
combin
oral
medic
metformin
glitazon
sulphonylurea
treatment
inhibitor
usual
accompani
improv
cell
function
improv
homeostasi
model
assess
beta
cell
function
index
fast
proinsulin
insulin
ratio
therapeut
effect
inhibitor
base
abil
degrad
incretin
peptid
inhibit
convers
increas
halflif
incretin
contribut
glucos
lower
postprandi
state
inhibitor
modestli
effect
sole
glucoselow
drug
lower
patient
start
level
around
howev
increasingli
use
clinic
due
safeti
drug
side
effect
incid
low
agent
report
side
effect
inhibitor
clinic
trial
includ
nasopharyng
upper
respiratori
tract
infect
urinari
tract
infect
headach
current
sever
inhibitor
approv
approv
fda
eu
may
broadli
divid
two
class
base
structur
dipeptid
structur
mimic
nonpeptidomimet
first
class
includ
sitagliptin
fda
addit
approv
drug
inhibitor
includ
dutogliptin
gemigliptin
develop
await
fda
approv
shown
inflamm
major
contributor
insulin
resist
innat
immun
adapt
immun
respons
develop
metaflamm
metabol
inflammatori
state
given
role
regul
cell
activ
may
import
regul
metaflamm
addit
bind
ada
membranebound
may
also
promot
cell
activ
clear
pericellular
adenosin
extracellular
adenosin
gener
atp
cell
surfac
excess
amount
adenosin
suppress
cell
prolifer
adenosin
degrad
ada
gener
inosin
nontox
product
lossoffunct
mutat
ada
could
caus
sever
combin
immunodefici
scid
human
mous
result
accumul
adenosin
jurkat
cell
mutant
devoid
ada
bind
activ
vulner
inhibitori
effect
prolifer
indic
immun
cell
facilit
adenosin
clearanc
bind
ada
fig
two
isoform
ada
ubiquit
express
present
cytosol
well
cell
membran
primari
role
degrad
adenosin
deoxyadenosin
predomin
isoform
found
plasma
unlik
possess
much
higher
costimulatori
activ
much
lower
capac
catalyz
adenosin
deamin
cell
may
also
interact
present
apc
initi
signal
cascad
antigen
load
apc
result
activ
upon
bind
phosphoryl
result
phosphoryl
eventu
nfkappa
b
nfkb
activ
activ
nfkb
turn
upregul
interact
report
involv
pathogenesi
arthriti
report
bind
multipl
compon
extracellular
matrix
collagen
fibronectin
tat
protein
interact
matrix
compon
may
play
role
sequestr
allow
addit
function
matrix
remodel
metastasi
chemotaxi
recent
work
suggest
express
apc
includ
macrophag
dendrit
cell
also
promot
metaflamm
interact
ada
level
adipos
tissu
inflammatori
cell
higher
counterpart
circul
express
viscer
adipos
tissu
increas
obes
patient
posit
correl
level
degre
insulin
resist
homair
evid
suggest
apcexpress
promot
cell
prolifer
activ
independ
catalyt
activ
catalyt
inhibit
addit
exogen
solubl
effect
vitro
cocultur
experi
suggest
apc
abl
anchor
ada
cell
surfac
modul
pericellular
microenviron
clear
adenosin
result
suggest
involv
noncatalyt
function
adipos
inflamm
diabet
recent
other
demonstr
inhibitor
confer
cardioprotect
effect
addit
antiglycemia
effect
may
includ
incretindepend
independ
effect
includ
random
clinic
trial
patient
inhibit
therapi
patient
control
treatment
diabet
treatment
placebo
recent
metaanalysi
demonstr
inhibitor
safe
cardiovascular
standpoint
benefici
effect
decreas
advers
cardiovascular
event
compar
diabet
medic
placebo
studi
indic
agonist
substrat
improv
outcom
cardiovascular
diseas
suggest
time
receptor
express
cardiovascular
cell
includ
endotheli
cell
cardiomyocyt
coronari
smooth
muscl
cell
belong
g
proteincoupl
receptor
engag
lead
activ
adenyl
cyclas
stimulatori
gs
subunit
subsequ
accumul
camp
classic
respons
cell
pancreat
cell
exampl
cell
activ
activ
pka
subsequ
reduc
result
increas
increas
transcript
factor
insulin
via
campdepend
pathway
signal
may
also
induc
activ
increas
express
bclxl
two
antiapoptot
protein
compel
evid
indic
signal
involv
cardioprotect
effect
inhibit
exampl
shown
acut
infus
improv
endotheli
dysfunct
patient
type
diabet
agonist
also
shown
stimul
prolifer
human
coronari
arteri
endotheli
cell
eno
pka
pathway
inhibitor
increas
endotheli
progenitor
cell
epc
suggest
role
pathway
develop
epc
moreov
increas
left
ventricular
develop
pressur
coronari
flow
isol
mous
heart
studi
confirm
protect
effect
endotheli
cell
mediat
increas
nitric
oxid
product
effect
could
mediat
independ
pathway
sever
larg
scale
phase
phase
clinic
trial
assess
cardiovascular
effect
inhibitor
trial
includ
examin
examin
cardiovascular
outcom
alogliptin
versu
standard
care
patient
type
diabet
mellitu
acut
coronari
syndrom
alogliptin
teco
trial
evalu
cardiovascular
outcom
sitagliptin
sitagliptin
savortimi
saxagliptin
assess
vascular
outcom
record
patient
diabet
mellitusthrombolysi
myocardi
infarct
trial
saxagliptin
carolina
cardiovascular
outcom
studi
linagliptin
versu
glimepirid
patient
type
diabet
linagliptin
among
trial
examin
savortimi
recent
complet
examin
studi
diabet
patient
recent
b
day
myocardi
infarct
unstabl
angina
requir
hospit
random
treatment
alogliptin
placebo
patient
follow
period
month
median
month
alogliptin
treatment
improv
outcom
primari
endpoint
includ
death
cardiovascular
caus
nonfat
myocardi
infarct
nonfat
stroke
total
diabet
subject
histori
mi
document
atherosclerosi
least
one
hypertens
smoke
dyslipidemia
recruit
trial
savortimi
evalu
effect
saxagliptin
cardiovascular
outcom
composit
fig
ada
role
atp
metabol
atp
adp
convert
amp
membranebound
amp
catalyz
produc
adenosin
adenosin
degrad
ada
bound
membraneanchor
cardiovascular
death
nonfat
myocardi
infarct
nonfat
ischem
stroke
patient
random
saxagliptin
group
placebo
group
addit
antidiabet
agent
prescrib
throughout
studi
median
followup
time
year
maximum
year
improv
cardiovascular
outcom
observ
saxagliptin
treatment
group
compar
placebotr
patient
howev
hospit
rate
heart
failur
higher
saxagliptintr
subject
vs
hazard
ratio
ci
p
differ
multipl
safeti
endpoint
pancreat
cancer
hypoglycemia
observ
across
group
trial
trial
suggest
catalyt
inhibit
basic
safe
cardiovascular
standpoint
also
improv
cardiovascular
endpoint
sever
reason
discrep
clinic
trial
result
previou
report
inhibit
possess
benefici
cardiovascular
effect
one
possibl
reason
followup
period
trial
long
enough
observ
differ
treatment
group
placebo
group
median
followup
period
year
year
examin
savortimi
respect
anoth
possibl
reason
patient
group
receiv
antidiabet
treatment
throughout
studi
possibl
reason
neutral
effect
cardiovascular
endpoint
may
involv
substrat
mention
previous
substrat
includ
varieti
peptid
treatment
might
interfer
cover
cardiovascular
effect
inhibit
mani
substrat
npi
implic
diabet
cardiovascular
diseas
howev
also
possibl
catalyt
inhibit
alon
insuffici
improv
cardiovascular
outcom
express
endotheli
cell
may
mediat
cardiovascular
effect
independ
manner
although
function
signific
effect
fulli
elucid
incub
isol
aorta
ring
enzymat
inhibitor
provid
direct
evid
show
inhibit
relax
aorta
pathway
alogliptin
inhibitor
induc
eno
akt
phosphoryl
ser
ser
respect
parallel
rapid
increas
nitric
oxid
inhibit
src
kinas
decreas
eno
akt
phosphoryl
respons
alogliptin
contrast
lack
effect
insulin
mediat
activ
enosakt
suggest
alogliptin
mediat
vasodil
src
kinas
mediat
effect
enosakt
whether
exert
effect
directli
eno
function
mechan
exert
effect
remain
seen
also
shown
assist
reconstruct
vasculatur
promot
epc
pathway
wellstudi
substrat
regul
epc
compar
four
week
sitagliptin
versu
addit
treatment
ad
baselin
metformin
andor
sulfonylurea
therapi
diabet
patient
fadini
cowork
demonstr
patient
inhibit
increas
epc
increas
anim
hindlimb
ischemia
myocardi
infarct
studi
confirm
promot
effect
inhibit
vasculogenesi
also
mediat
home
engraft
progenitor
cell
transplant
enzymat
inhibit
delet
greatli
promot
home
engraft
mous
human
hematopoiet
progenitor
cell
via
mechan
involv
studi
suggest
truncat
colonystimul
factor
csf
gmcsf
gcsf
erythropoietin
also
involv
regul
progenitor
cell
home
engraft
howev
degrad
anoth
substrat
npi
suggest
promot
angiogenesi
enhanc
product
npi
npi
npi
shown
promot
human
umbil
endotheli
cell
migrat
endotheli
wound
assay
inhibit
activ
neutral
antibodi
suppress
angiogen
activ
npi
npi
suggest
product
npi
requir
angiogen
activ
npi
anoth
import
mechan
inhibit
proffer
cardiovascular
benefit
reduct
inflamm
inflamm
play
etiolog
role
develop
mainten
cardiovascular
diseas
also
known
tcell
antigen
addit
cardiovascular
cell
also
highli
express
mani
inflammatori
cell
includ
cell
monocyt
regul
biolog
process
function
enzymat
nonenzymat
function
play
import
role
cell
activ
cell
activ
block
enzymat
inhibit
suppress
dipeptidas
activ
result
reduc
product
cytokin
includ
peripher
blood
mononuclear
cell
cell
immunosuppress
cytokin
shown
upregul
inhibit
cell
transfect
mutant
devoid
enzymat
activ
display
reduc
activ
compar
transfect
wildtyp
consist
addit
solubl
promot
recal
antigeninduc
prolifer
peripher
blood
lymphocyt
solubl
mutant
without
enzymat
activ
provid
direct
evid
enzymat
activ
involv
cell
activ
enzymat
activ
nonenzymat
function
also
import
cell
activ
shown
abl
directli
bind
sever
extracellular
molecul
ada
adenosin
deaminas
collagen
fibronectin
engag
ada
antibodi
induc
costimulatori
signal
activ
tcell
interact
membranelink
tyrosin
phosphatas
follow
activ
cell
percentag
cell
number
molecul
per
cell
elev
tcell
activ
requir
complex
engag
induc
cytotox
clone
clone
furthermor
downregul
antibodi
preincub
markedli
reduc
tcell
prolifer
activ
enhanc
tyrosin
phosphoryl
chain
induc
product
addit
phosphoryl
rang
intracellular
protein
involv
signal
map
kinas
ccbl
phospholipas
increas
prolong
crosslink
tcell
also
regul
function
antigenpres
cell
apc
includ
macrophag
dendrit
cell
solubl
report
abl
upregul
express
apc
thu
enhanc
antigen
present
function
addit
studi
demonstr
directli
bind
cell
surfac
apc
interact
express
apc
mediat
signal
cascad
antigen
load
apc
result
activ
bind
induc
phosphoryl
subsequ
activ
recent
show
macrophag
dendrit
cell
import
inflammatori
function
bind
ada
apcexpress
provid
microenviron
suitabl
cell
prolifer
enhanc
viscer
adipos
inflamm
addit
ada
report
bind
multipl
extracellular
matrix
compon
includ
collagen
fibronectin
interact
matrix
may
play
role
matrix
remodel
metastasi
chemotaxi
develop
applic
specif
inhibitor
clinic
reemphas
import
physiolog
patholog
process
recent
studi
suggest
implic
cardiovascular
diseas
noncatalyt
activ
may
also
play
role
metabol
dysfunct
howev
detail
involv
variou
biolog
process
diseas
fulli
elucid
studi
requir
explor
implic
work
support
grant
aha
nsfc
dr
zhong
author
declar
conflict
interest
paper
